Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models.

Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, Baeriswyl JL, Cavegn N, Senn L, Su L, Marsh G, Auluck PK, Montrasio F, Nitsch RM, Hirst WD, Cedarbaum JM, Pepinsky RB, Grimm J, Weinreb PH.

Neurobiol Dis. 2019 Apr;124:276-288. doi: 10.1016/j.nbd.2018.10.016. Epub 2018 Oct 28.

2.

Potent α-Synuclein Aggregation Inhibitors, Identified by High-Throughput Screening, Mainly Target the Monomeric State.

Kurnik M, Sahin C, Andersen CB, Lorenzen N, Giehm L, Mohammad-Beigi H, Jessen CM, Pedersen JS, Christiansen G, Petersen SV, Staal R, Krishnamurthy G, Pitts K, Reinhart PH, Mulder FAA, Mente S, Hirst WD, Otzen DE.

Cell Chem Biol. 2018 Nov 15;25(11):1389-1402.e9. doi: 10.1016/j.chembiol.2018.08.005. Epub 2018 Sep 6.

PMID:
30197194
3.

Self-report data as a tool for subtype identification in genetically-defined Parkinson's Disease.

Winslow AR, Hyde CL, Wilk JB, Eriksson N, Cannon P, Miller MR, Hirst WD.

Sci Rep. 2018 Aug 28;8(1):12992. doi: 10.1038/s41598-018-30843-6.

4.

GBA mutations in Parkinson disease: earlier death but similar neuropathological features.

Adler CH, Beach TG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Patel A, Sue LI, Serrano G, Jacobson SA, Davis K, Belden CM, Dugger BN, Paciga SA, Winslow AR, Hirst WD, Hentz JG.

Eur J Neurol. 2017 Nov;24(11):1363-1368. doi: 10.1111/ene.13395. Epub 2017 Aug 17.

5.

The Role of Astrocyte Dysfunction in Parkinson's Disease Pathogenesis.

Booth HDE, Hirst WD, Wade-Martins R.

Trends Neurosci. 2017 Jun;40(6):358-370. doi: 10.1016/j.tins.2017.04.001. Epub 2017 May 17. Review.

6.

Sonic hedgehog signalling mediates astrocyte crosstalk with neurons to confer neuroprotection.

Ugbode CI, Smith I, Whalley BJ, Hirst WD, Rattray M.

J Neurochem. 2017 Aug;142(3):429-443. doi: 10.1111/jnc.14064. Epub 2017 Jun 20.

7.

G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.

Volpicelli-Daley LA, Abdelmotilib H, Liu Z, Stoyka L, Daher JP, Milnerwood AJ, Unni VK, Hirst WD, Yue Z, Zhao HT, Fraser K, Kennedy RE, West AB.

J Neurosci. 2016 Jul 13;36(28):7415-27. doi: 10.1523/JNEUROSCI.3642-15.2016.

8.

Astrocytes Grown in Alvetex(®) Three Dimensional Scaffolds Retain a Non-reactive Phenotype.

Ugbode CI, Hirst WD, Rattray M.

Neurochem Res. 2016 Aug;41(8):1857-67. doi: 10.1007/s11064-016-1911-3. Epub 2016 Apr 21.

PMID:
27099962
9.

A Rapid, Semi-Quantitative Assay to Screen for Modulators of Alpha-Synuclein Oligomerization Ex vivo.

Delenclos M, Trendafilova T, Jones DR, Moussaud S, Baine AM, Yue M, Hirst WD, McLean PJ.

Front Neurosci. 2016 Jan 19;9:511. doi: 10.3389/fnins.2015.00511. eCollection 2015.

10.

DISC1-dependent Regulation of Mitochondrial Dynamics Controls the Morphogenesis of Complex Neuronal Dendrites.

Norkett R, Modi S, Birsa N, Atkin TA, Ivankovic D, Pathania M, Trossbach SV, Korth C, Hirst WD, Kittler JT.

J Biol Chem. 2016 Jan 8;291(2):613-29. doi: 10.1074/jbc.M115.699447. Epub 2015 Nov 9.

11.

Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.

Henry AG, Aghamohammadzadeh S, Samaroo H, Chen Y, Mou K, Needle E, Hirst WD.

Hum Mol Genet. 2015 Nov 1;24(21):6013-28. doi: 10.1093/hmg/ddv314. Epub 2015 Aug 6.

PMID:
26251043
12.

Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.

Daher JP, Abdelmotilib HA, Hu X, Volpicelli-Daley LA, Moehle MS, Fraser KB, Needle E, Chen Y, Steyn SJ, Galatsis P, Hirst WD, West AB.

J Biol Chem. 2015 Aug 7;290(32):19433-44. doi: 10.1074/jbc.M115.660001. Epub 2015 Jun 15.

13.

Tool compounds robustly increase turnover of an artificial substrate by glucocerebrosidase in human brain lysates.

Berger Z, Perkins S, Ambroise C, Oborski C, Calabrese M, Noell S, Riddell D, Hirst WD.

PLoS One. 2015 Mar 12;10(3):e0119141. doi: 10.1371/journal.pone.0119141. eCollection 2015.

14.

Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.

Henderson JL, Kormos BL, Hayward MM, Coffman KJ, Jasti J, Kurumbail RG, Wager TT, Verhoest PR, Noell GS, Chen Y, Needle E, Berger Z, Steyn SJ, Houle C, Hirst WD, Galatsis P.

J Med Chem. 2015 Jan 8;58(1):419-32. doi: 10.1021/jm5014055. Epub 2014 Nov 17.

PMID:
25353650
15.

Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.

Galatsis P, Henderson JL, Kormos BL, Han S, Kurumbail RG, Wager TT, Verhoest PR, Noell GS, Chen Y, Needle E, Berger Z, Steyn SJ, Houle C, Hirst WD.

Bioorg Med Chem Lett. 2014 Sep 1;24(17):4132-40. doi: 10.1016/j.bmcl.2014.07.052. Epub 2014 Jul 30.

PMID:
25113930
16.

Neuronal influences are necessary to produce mitochondrial co-localization with glutamate transporters in astrocytes.

Ugbode CI, Hirst WD, Rattray M.

J Neurochem. 2014 Sep;130(5):668-77. doi: 10.1111/jnc.12759. Epub 2014 Jun 16.

17.

Lysine 27 ubiquitination of the mitochondrial transport protein Miro is dependent on serine 65 of the Parkin ubiquitin ligase.

Birsa N, Norkett R, Wauer T, Mevissen TE, Wu HC, Foltynie T, Bhatia K, Hirst WD, Komander D, Plun-Favreau H, Kittler JT.

J Biol Chem. 2014 May 23;289(21):14569-82. doi: 10.1074/jbc.M114.563031. Epub 2014 Mar 26.

18.

Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons.

Shen W, Henry AG, Paumier KL, Li L, Mou K, Dunlop J, Berger Z, Hirst WD.

J Neurochem. 2014 Jun;129(5):884-94. doi: 10.1111/jnc.12672. Epub 2014 Mar 3.

19.

Human A53T α-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neurons.

Li L, Nadanaciva S, Berger Z, Shen W, Paumier K, Schwartz J, Mou K, Loos P, Milici AJ, Dunlop J, Hirst WD.

PLoS One. 2013 Dec 31;8(12):e85815. doi: 10.1371/journal.pone.0085815. eCollection 2013.

20.

Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1.

Luerman GC, Nguyen C, Samaroo H, Loos P, Xi H, Hurtado-Lorenzo A, Needle E, Stephen Noell G, Galatsis P, Dunlop J, Geoghegan KF, Hirst WD.

J Neurochem. 2014 Feb;128(4):561-76. doi: 10.1111/jnc.12483. Epub 2013 Nov 11.

21.

Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif.

Pungaliya PP, Bai Y, Lipinski K, Anand VS, Sen S, Brown EL, Bates B, Reinhart PH, West AB, Hirst WD, Braithwaite SP.

PLoS One. 2010 Oct 27;5(10):e13672. doi: 10.1371/journal.pone.0013672.

22.

Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer's disease.

Braithwaite SP, Schmid RS, He DN, Sung ML, Cho S, Resnick L, Monaghan MM, Hirst WD, Essrich C, Reinhart PH, Lo DC.

Neurobiol Dis. 2010 Sep;39(3):311-7. doi: 10.1016/j.nbd.2010.04.015. Epub 2010 May 6.

23.

The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists.

Childers WE Jr, Havran LM, Asselin M, Bicksler JJ, Chong DC, Grosu GT, Shen Z, Abou-Gharbia MA, Bach AC 3rd, Harrison BL, Kagan N, Kleintop T, Magolda R, Marathias V, Robichaud AJ, Sabb AL, Zhang MY, Andree TH, Aschmies SH, Beyer C, Comery TA, Day M, Grauer SM, Hughes ZA, Rosenzweig-Lipson S, Platt B, Pulicicchio C, Smith DE, Sukoff-Rizzo SJ, Sullivan KM, Adedoyin A, Huselton C, Hirst WD.

J Med Chem. 2010 May 27;53(10):4066-84. doi: 10.1021/jm1000908.

PMID:
20443629
24.

Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors.

Donnell AF, Dollings PJ, Butera JA, Dietrich AJ, Lipinski KK, Ghavami A, Hirst WD.

Bioorg Med Chem Lett. 2010 Apr 1;20(7):2163-7. doi: 10.1016/j.bmcl.2010.02.044. Epub 2010 Feb 13.

PMID:
20202838
25.

Benzimidazole- and indole-substituted 1,3'-bipyrrolidine benzamides as histamine H3 receptor antagonists.

Cole DC, Gross JL, Comery TA, Aschmies S, Hirst WD, Kelley C, Kim JI, Kubek K, Ning X, Platt BJ, Robichaud AJ, Solvibile WR, Stock JR, Tawa G, Williams MJ, Ellingboe JW.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1237-40. doi: 10.1016/j.bmcl.2009.11.122. Epub 2009 Dec 4.

PMID:
20042333
26.

Sonic Hedgehog signaling in astrocytes is dependent on p38 mitogen-activated protein kinase and G-protein receptor kinase 2.

Atkinson PJ, Dellovade T, Albers D, Von Schack D, Saraf K, Needle E, Reinhart PH, Hirst WD.

J Neurochem. 2009 Mar;108(6):1539-49. doi: 10.1111/j.1471-4159.2009.05900.x. Epub 2009 Jan 22.

27.

Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays.

Anand VS, Reichling LJ, Lipinski K, Stochaj W, Duan W, Kelleher K, Pungaliya P, Brown EL, Reinhart PH, Somberg R, Hirst WD, Riddle SM, Braithwaite SP.

FEBS J. 2009 Jan;276(2):466-78. doi: 10.1111/j.1742-4658.2008.06789.x.

28.

The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats.

Foley AG, Hirst WD, Gallagher HC, Barry C, Hagan JJ, Upton N, Walsh FS, Hunter AJ, Regan CM.

Neuropharmacology. 2008 Jun;54(8):1166-74. doi: 10.1016/j.neuropharm.2008.03.012. Epub 2008 Apr 1.

PMID:
18455201
29.

Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory.

Liu F, Day M, Muñiz LC, Bitran D, Arias R, Revilla-Sanchez R, Grauer S, Zhang G, Kelley C, Pulito V, Sung A, Mervis RF, Navarra R, Hirst WD, Reinhart PH, Marquis KL, Moss SJ, Pangalos MN, Brandon NJ.

Nat Neurosci. 2008 Mar;11(3):334-43. doi: 10.1038/nn2057. Epub 2008 Feb 24.

PMID:
18297067
30.

Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405).

Hirst WD, Andree TH, Aschmies S, Childers WE, Comery TA, Dawson LA, Day M, Feingold IB, Grauer SM, Harrison BL, Hughes ZA, Kao J, Kelly MG, van der Lee H, Rosenzweig-Lipson S, Saab AL, Smith DL, Sullivan K, Rizzo SJ, Tio C, Zhang MY, Schechter LE.

J Pharmacol Exp Ther. 2008 Apr;325(1):134-45. doi: 10.1124/jpet.107.133082. Epub 2008 Jan 8.

PMID:
18182558
31.

The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease.

Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, Reinhart PH, Jacobsen JS.

Mol Cell Neurosci. 2007 Apr;34(4):621-8. Epub 2007 Jan 25.

PMID:
17336088
32.

GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.

Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, Cilia J, Cluderay JE, Crook B, Davis JB, Davis RK, Davis RP, Dawson LA, Foley AG, Gartlon J, Gonzalez MI, Heslop T, Hirst WD, Jennings C, Jones DN, Lacroix LP, Martyn A, Ociepka S, Ray A, Regan CM, Roberts JC, Schogger J, Southam E, Stean TO, Trail BK, Upton N, Wadsworth G, Wald JA, White T, Witherington J, Woolley ML, Worby A, Wilson DM.

J Pharmacol Exp Ther. 2007 Jun;321(3):1032-45. Epub 2007 Feb 27.

PMID:
17327487
33.

Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.

Medhurst AD, Briggs MA, Bruton G, Calver AR, Chessell I, Crook B, Davis JB, Davis RP, Foley AG, Heslop T, Hirst WD, Medhurst SJ, Ociepka S, Ray A, Regan CM, Sargent B, Schogger J, Stean TO, Trail BK, Upton N, White T, Orlek B, Wilson DM.

Biochem Pharmacol. 2007 Apr 15;73(8):1182-94. Epub 2007 Jan 7.

PMID:
17276409
34.

Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test.

Day M, Pan JB, Buckley MJ, Cronin E, Hollingsworth PR, Hirst WD, Navarra R, Sullivan JP, Decker MW, Fox GB.

Biochem Pharmacol. 2007 Apr 15;73(8):1123-34. Epub 2006 Dec 9.

PMID:
17214974
35.

SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models.

Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF, Bromidge SM, Riley G, Smith DR, Bartlett S, Heidbreder CA, Atkins AR, Lacroix LP, Dawson LA, Foley AG, Regan CM, Upton N.

Eur J Pharmacol. 2006 Dec 28;553(1-3):109-19. Epub 2006 Sep 29.

PMID:
17069795
36.
37.

Selective phosphodiesterase (PDE)-4 inhibitors: a novel approach to treating memory deficit?

Ghavami A, Hirst WD, Novak TJ.

Drugs R D. 2006;7(2):63-71. Review.

PMID:
16542053
39.

The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats.

Foley AG, Murphy KJ, Hirst WD, Gallagher HC, Hagan JJ, Upton N, Walsh FS, Regan CM.

Neuropsychopharmacology. 2004 Jan;29(1):93-100.

40.

Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease.

Garcia-Alloza M, Hirst WD, Chen CP, Lasheras B, Francis PT, Ramírez MJ.

Neuropsychopharmacology. 2004 Feb;29(2):410-6.

41.

Pharmacological characterisation of a cell line expressing GABA B1b and GABA B2 receptor subunits.

Hirst WD, Babbs AJ, Green A, Minton JA, Shaw TE, Wise A, Rice SQ, Pangalos MN, Price GW.

Biochem Pharmacol. 2003 Apr 1;65(7):1103-13.

PMID:
12663046
42.

Cyclic AMP-dependent protein kinase phosphorylation facilitates GABA(B) receptor-effector coupling.

Couve A, Thomas P, Calver AR, Hirst WD, Pangalos MN, Walsh FS, Smart TG, Moss SJ.

Nat Neurosci. 2002 May;5(5):415-24.

PMID:
11976702
43.

Pharmacological profile of SB-357134: a potent, selective, brain penetrant, and orally active 5-HT(6) receptor antagonist.

Stean TO, Hirst WD, Thomas DR, Price GW, Rogers D, Riley G, Bromidge SM, Serafinowska HT, Smith DR, Bartlett S, Deeks N, Duxon M, Upton N.

Pharmacol Biochem Behav. 2002 Apr;71(4):645-54.

PMID:
11888556
44.

Gabapentin is not a GABAB receptor agonist.

Lanneau C, Green A, Hirst WD, Wise A, Brown JT, Donnier E, Charles KJ, Wood M, Davies CH, Pangalos MN.

Neuropharmacology. 2001 Dec;41(8):965-75.

PMID:
11747901
45.

GABA(B2) is essential for g-protein coupling of the GABA(B) receptor heterodimer.

Robbins MJ, Calver AR, Filippov AK, Hirst WD, Russell RB, Wood MD, Nasir S, Couve A, Brown DA, Moss SJ, Pangalos MN.

J Neurosci. 2001 Oct 15;21(20):8043-52.

46.

Epileptogenesis and enhanced prepulse inhibition in GABA(B1)-deficient mice.

Prosser HM, Gill CH, Hirst WD, Grau E, Robbins M, Calver A, Soffin EM, Farmer CE, Lanneau C, Gray J, Schenck E, Warmerdam BS, Clapham C, Reavill C, Rogers DC, Stean T, Upton N, Humphreys K, Randall A, Geppert M, Davies CH, Pangalos MN.

Mol Cell Neurosci. 2001 Jun;17(6):1059-70.

PMID:
11414794
47.
48.

The C-terminal domains of the GABA(b) receptor subunits mediate intracellular trafficking but are not required for receptor signaling.

Calver AR, Robbins MJ, Cosio C, Rice SQ, Babbs AJ, Hirst WD, Boyfield I, Wood MD, Russell RB, Price GW, Couve A, Moss SJ, Pangalos MN.

J Neurosci. 2001 Feb 15;21(4):1203-10.

49.

The human GABA(B1b) and GABA(B2) heterodimeric recombinant receptor shows low sensitivity to phaclofen and saclofen.

Wood MD, Murkitt KL, Rice SQ, Testa T, Punia PK, Stammers M, Jenkins O, Elshourbagy NA, Shabon U, Taylor SJ, Gager TL, Minton J, Hirst WD, Price GW, Pangalos M.

Br J Pharmacol. 2000 Nov;131(6):1050-4.

50.

Characterization of the binding of [(125)I]-human prolactin releasing peptide (PrRP) to GPR10, a novel G protein coupled receptor.

Langmead CJ, Szekeres PG, Chambers JK, Ratcliffe SJ, Jones DN, Hirst WD, Price GW, Herdon HJ.

Br J Pharmacol. 2000 Oct;131(4):683-8.

Supplemental Content

Loading ...
Support Center